107 related articles for article (PubMed ID: 31593970)
1. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L; Carmosino I; Breccia M; De Benedittis D; Mohamed S; De Luca ML; Colafigli G; Molica M; Scalzulli E; Massaro F; Mariggiò E; Rizzo L; Loglisci MG; Scamuffa MC; Vozella F; Diverio D; Mancini M; Alimena G; Foà R; Latagliata R
Oncol Res Treat; 2019; 42(12):660-664. PubMed ID: 31593970
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Cesini L; Frieri C; Baratè C; Sorà F; Bonifacio M; Cerrano M; Cagnetta A; Elena C; Aprile L; Sgherza N; Trawinska M; Gozzini A; Capodanno I; Crugnola M; Carmosino I; Scalzulli E; Ricci F; Bocchia M; Bergamaschi M; Aguzzi C; Sica S; Galimberti S; Breccia M; Luciano L; Latagliata R
Eur J Haematol; 2020 Sep; 105(3):286-291. PubMed ID: 32365249
[TBL] [Abstract][Full Text] [Related]
3. Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.
Latagliata R; Volpicelli P; Breccia M; Vozella F; Romano A; Montagna C; Molica M; Finsinger P; Carmosino I; Serrao A; Zacheo I; Santopietro M; Salaroli A; Alimena G
Am J Hematol; 2015 Feb; 90(2):105-8. PubMed ID: 25349084
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
[TBL] [Abstract][Full Text] [Related]
5. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
7. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
Sakurai M; Kikuchi T; Karigane D; Kasahara H; Matsuki E; Hashida R; Yamane Y; Abe R; Koda Y; Toyama T; Kato J; Shimizu T; Yokoyama Y; Suzuki S; Nakamura T; Okamoto S; Mori T
Int J Hematol; 2019 Mar; 109(3):292-298. PubMed ID: 30680668
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
9. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
11. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
[TBL] [Abstract][Full Text] [Related]
12. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
13. [Impact of age on the clinical response of patients with CML treated with imatinib].
Bělohlávková P; Voglová J; Radocha J; Žák P
Vnitr Lek; 2015 Sep; 61(9):785-6, 788-91. PubMed ID: 26465277
[TBL] [Abstract][Full Text] [Related]
14. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
15. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
[TBL] [Abstract][Full Text] [Related]
16. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter.
Belohlavkova P; Steinerova K; Karas M; Skoumalova I; Rohon P; Indrak K; Voglova J; Vrbacky F; Cmunt E; Necasova T; Kristkova Z; Trneny M; Zak P; Papajik T; Faber E
Leuk Res; 2019 Jun; 81():67-74. PubMed ID: 31051328
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
18. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
19. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A; Larson RA; Guilhot F; Radich JP; Branford S; Hughes TP; Baccarani M; Deininger MW; Cervantes F; Fujihara S; Ortmann CE; Menssen HD; Kantarjian H; O'Brien SG; Druker BJ;
N Engl J Med; 2017 Mar; 376(10):917-927. PubMed ID: 28273028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
